Marcus Munafò is Professor of Biological Psychology at the University of Bristol, United Kingdom. His research interests are primarily in the area of behavioural and neurobiological mechanisms of tobacco and alcohol use. He completed his PhD in 2000 at the University of Southampton, and worked as a postdoctoral fellow at the University of Oxford and the University Pennsylvania before taking up a permanent position at Bristol in 2005. You can follow him on Twitter @MarcusMunafo and his research group @BristolTARG
Marcus Munafo looks at a Chinese genome-wide association study that claims to have identified some of the genes associated with response to antipsychotic treatment.
Marcus Munafo considers the findings of a systematic review of meta-analyses of observational studies, which looks at risk factors and peripheral biomarkers for psychotic disorders on the schizophrenia spectrum.
Marcus Munafo comments on a review of the work of the Psychiatric Genomics Consortium, which in recent years has delivered an increasing flow of new knowledge about the fundamental basis of common psychiatric disorders.
Marcus Munafò reports on a new genome-wide association study that identifies 44 risk variants and helps us to further refine the genetic architecture of major depressive disorder.
Marcus Munafo looks at a complex and sophisticated series of experiments that provide further insight into the relationships between genetic risk, cigarette smoking and schizophrenia.
Marcus Munafo explores a recent study that uses genetic data and family environmental information to quantify the risk of chronic pain and the contribution of risk variants for major depressive disorder.
Marcus Munafo considers the implications of a recent Swedish population study, which explores patterns of non-random mating within and across 11 major psychiatric disorders.
Marcus Munafo explores a recent study that uses a machine learning approach across two trials (STARD*D and CO-MED) to try and predict treatment outcomes (primarily focusing on the antidepressant citalopram) for depression.
